| Business Summary | | Alexion
Pharmaceuticals
develops
products
for
the
treatment
of
heart
disease,
and
inflammation,
diseases
of
the
immune
system
and
cancer
in
humans.
The
Company's
lead
product
candidates
are
genetically
altered
antibodies
that
target
specific
diseases
that
arise
when
the
human
immune
system
induces
undesired
inflammation
in
the
human
body.
The
Company's
lead
product
candidates
are
designed
to
block
components
of
the
human
immune
system
that
cause
inflammation
while
allowing
beneficial
components
of
the
immune
system
to
remain
functional.
The
Company's
two
lead
genetically
altered
antibody
product
candidates
are
designed
to
block
the
inflammatory
effects
of
the
components
of
the
immune
system
known
as
"complement,"
and
are
5G1.1-SC
for
the
treatment
of
acute
inflammation
caused
by
the
trauma
of
heart
and
lung
bypass
procedures
during
open
heart
surgery
and
5G1.1
for
the
chronic
treatment
of
rheumatoid
arthritis,
membranous
nephritis
and
psoriasis,
dermatomyositis
and
bullous
pemphigoid. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Alexion
Pharmaceuticals
is
a
biopharmaceutical
company
engaged
in
the
development
of
products
for
the
treatment
of
cardiovascular,
autoimmune
and
neurologic
diseases.
For
the
nine
months
ended
4/30/01,
revenues
fell
51%
to
$8.5
million.
Net
loss
before
acctg.
chg.
totaled
$40.4
million,
up
from
$15.1
million.
Results
reflect
decreased
contract
revenues
due
to
lower
related
expense
reimbursements
from
Proctor
and
Gamble.
Higher
loss
reflects
a
$21
million
in-process
R&D
charge. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| John Fried, Ph.D., 70 Chairman | -- | Leonard Bell, M.D., 42 Pres,
CEO, Sec., Treasurer, Director | $436K | David Keiser, 49 Exec.
VP, COO | 260K | Stephen Squinto, Ph.D., 44 Exec.
VP and Head of Research | 223K | Barry Luke, 42 VP-Fin.,
VP-Admin., Assistant Sec. | -- | Dollar amounts are as of 31-July-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|